3549.T Kusuri No Aoki JPX pre-market earnings 31 Mar 2026: guidance will shape targets

3549.T stock is trading in the JPX pre-market at JPY 3,869.00, up 3.53% on higher volume as investors position ahead of Kusuri No Aoki Holdings’ earnings due 02 Apr 2026. The move follows a 50-day average of JPY 4,129.14 and a 200-day average of JPY 3,951.56, leaving traders focused on guidance and margin detail in the report. We outline valuation, Meyka AI forecast, and realistic price targets to watch before the official announcement.

Earnings catalyst and timing for 3549.T stock

Kusuri No Aoki Holdings (3549.T) will release results on 02 Apr 2026, and the pre-market rise to JPY 3,869.00 reflects elevated expectations for margin improvement. Analysts will focus on same-store sales, pharmacy dispensing margins, and management guidance for FY2026 because these items historically move the stock.

The company reports EPS of JPY 186.85 (trailing twelve months) and a trailing PE of 20.47, so the earnings update could re-rate expectations if management revises guidance materially.

Recent financials and valuation snapshot

On key metrics Kusuri No Aoki shows revenue per share JPY 5,549.39 and net income per share JPY 193.79, with a market cap of JPY 364,375,952,775.00. Price-to-sales is 0.68 and price-to-book is 2.79, while net margin sits near 3.49%, highlighting thin retail margins relative to peers.

Compared with the Healthcare sector average PE of 24.23, 3549.T stock trades at a modest discount on PE. Balance-sheet ratios show debt-to-equity 1.04 and interest coverage 31.12, indicating manageable interest costs but higher leverage than some healthcare peers.

Meyka AI grade and model forecast for 3549.T stock

Meyka AI rates 3549.T with a score out of 100: 69.74/100 (Grade B, HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst sentiment. The grade reflects solid ROE 13.23%, moderate valuation, and mixed cash-flow trends.

Meyka AI’s forecast model projects a 12-month price of JPY 4,213.44, a monthly target JPY 4,249.71, and a quarterly target JPY 4,355.29. Versus the current price JPY 3,869.00, the yearly projection implies an upside of 8.90%. Forecasts are model-based projections and not guarantees.

Technical and pre-market trading setup

Pre-market technicals show a daily range between JPY 3,774.00 and JPY 3,876.00, with volume 448,600 shares and avg volume 373,003. RSI sits around 48.69, Bollinger middle band JPY 3,750.10, and the MACD histogram has turned positive, signaling short-term momentum.

Key technical levels to watch are support near the day low JPY 3,774.00 and resistance at the 50-day average JPY 4,129.14. Traders should monitor on-balance volume and ATR JPY 105.40 for volatility cues immediately after the release.

Analyst signals, consensus and price-target context

Public analyst data is limited; a recent company rating shows a mixed view with a B- and a Sell recommendation on specific DCF inputs. Investors should note the absence of a consolidated broker price-target consensus and rely on company guidance and Meyka forecasts for short-term pricing.

Reuters coverage has tracked company listings and financials ahead of the report source and source. Use those filings plus the earnings release to update targets; a near-term tactical target from Meyka is JPY 4,250.00, with a 12-month base case near JPY 4,350.00.

Risks and opportunities for investors in 3549.T stock

Opportunities include steady same-store growth from the retail pharmacy network and improving operating margins if generic substitution improves mix. The company’s ROIC 6.89% and ROE 13.23% show operational efficiency that could re-rate the stock on positive guidance.

Risks include retail margin pressure, slower cash-flow growth (operating cash flow trends are mixed), and above-average leverage with debt-to-equity 1.04. Regulatory changes in drug pricing or a weak consumer retail cycle in Japan would hurt near-term results.

Final Thoughts

Key takeaway: 3549.T stock trades at JPY 3,869.00 in the JPX pre-market with momentum ahead of Kusuri No Aoki Holdings’ earnings on 02 Apr 2026. Our Meyka AI forecast model projects a 12-month price of JPY 4,213.44, implying an upside of 8.90% versus the current price. Valuation metrics — PE 20.47, P/S 0.68, and PB 2.79 — suggest the stock is reasonably priced against the Healthcare sector but sensitive to guidance and retail margin swings. Traders should watch same-store sales, dispensing margins, and management guidance; a beat plus upward guidance could push price toward the JPY 4,250.00–4,350.00 range, while soft guidance could test support near JPY 3,774.00. This analysis uses data from public filings and Meyka AI’s models; forecasts are projections, not guarantees. As an AI-powered market analysis platform, Meyka AI provides data-driven insights to frame expectations, but investors should combine this with direct filings and broker notes before acting.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.